Phathom Pharmaceuticals, Inc. (PHAT)
| Market Cap | 618.13M |
| Revenue (ttm) | 2.59M |
| Net Income (ttm) | -246.63M |
| Shares Out | 58.54M |
| EPS (ttm) | -4.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 418,387 |
| Open | 10.72 |
| Previous Close | 10.69 |
| Day's Range | 10.25 - 10.77 |
| 52-Week Range | 6.07 - 17.02 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 22.00 (+108.73%) |
| Earnings Date | May 9, 2024 |
About PHAT
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is head... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PHAT stock is "Strong Buy." The 12-month stock price forecast is $22.0, which is an increase of 108.73% from the latest price.
News
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe...
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
Management to host conference call on Thursday, March 7, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J.
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
FLORHAM PARK, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
FLORHAM PARK, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA ta...
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
FLORHAM PARK, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
FLORHAM PARK, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
NEW YORK , Oct. 23, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary dut...
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
FLORHAM PARK, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
FLORHAM PARK, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
FLORHAM PARK, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
NEW YORK , June 9, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom Pharmaceuticals, I...
PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.
NEW YORK , June 8, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) concerning possible viola...
PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.
NEW YORK , May 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) violated federal securities laws...
PHAT ALERT: The Law Offices of Vincent Wong Investigate Phathom Pharmaceuticals, Inc. for Potential Violations of Securities Laws
NEW YORK , May 31, 2023 /PRNewswire/ -- Attention Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced in...
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe...
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe...
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe...